Director General ellwood atfield | Brussels

Ellwood Atfield has been retained to recruit a new Director General (DG) for the European Generic Medicines Association (EGA).

The EGA is the official representative body of the European generic and biosimilar pharmaceutical industry. It is at the forefront of providing high-quality affordable medicines to millions of Europeans and stimulating competitiveness and innovation in the pharmaceutical sector. Formed in 1993, the EGA represents generic pharmaceutical companies and their subsidiaries throughout Europe, either directly or through national associations. Companies represented within the EGA provide over 150,000 jobs in Europe. Cost-effective generic medicines save EU patients and healthcare systems over €35 billion each year, thus helping to ensure patient access to essential medicines and providing urgently needed budget headroom for the purchase of new and innovative treatments.

The EGA plays an important consultative part in European healthcare policy-making and provides a key educational role for its members. The EGA and its members work with European national governments and the EU institutions to develop affordable solutions for pharmaceutical care and to increase Europe’s competitive strength in the global pharmaceutical medicines market. EGA has 32 full and affiliate corporate members and 19 national association members from all over Europe.

The principal role of the DG is to advocate for and communicate the interests of the generic medicines industry at a European Union level to key stakeholders including policy-makers, health stakeholders and the media.

The Director General candidate specification is described in greater detail in the attached document.

To apply, please contact mark@ellwoodatfield.com